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Diabetic retinopathy (DR) is among the leading causes of new onset blindness in adults.
Effective treatment may delay the onset and progression of this disease provided it is
diagnosed early. At present retinopathy can only be diagnosed via formal examination
of the eye by a trained specialist, which limits the population that can be effectively
screened. An easily accessible, reliable screening biomarker of diabetic retinopathy
would be of tremendous benefit in detecting the population in need of further assessment
and treatment. This review highlights specific biomarkers that show promise as screening
markers to detect early diabetic retinopathy or even to detect patients at increased risk
of DR at the time of diagnosis of diabetes. The pathobiology of DR is complex and
multifactorial giving rise to a wide array of potential biomarkers. This review provides an
overview of these pathways and looks at older markers such as advanced glycation end
products (AGEs), inflammatory markers, vascular endothelial growth factor (VEGF) as well
as other newer proteins with a role in the pathogenesis of DR including neuroprotective
factors such as brain derived neurotrophic factor (BDNF) and Pigment Epithelium Derived
Factor (PEDF); SA100A12, pentraxin 3, brain natriuretic peptide, apelin 3, and chemerin
as well as various metabolites such as lipoprotein A, folate, and homocysteine. We also
consider the possible role of proteins identified through proteomics work whose levels
are altered in the sera of patients with DR as screening markers though their role in
pathophysiology remains to be characterized. The role of microRNA as a promising new
screening marker is also discussed.
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INTRODUCTION
Diabetes mellitus (DM) is associated with a wide range of microvascular complications including
diabetic retinopathy (DR). One of the main risk factors associated with development of DR is
poorly controlled blood sugar as assessed by glycated hemoglobin levels (HbA1c)—the higher the
HbA1c, the greater the risk of developing retinopathy (Hiller et al., 1988). Legal blindness due to
DR is estimated to be 25 times more common among the diabetic population than in those without
diabetes (Aiello et al., 2001).
The range of treatments currently available for DM has dramatically increased the lifespan of
diabetic patients, allowing time for clinically significant microvascular complications to develop.
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DR is currently estimated to be the leading cause of new onset
blindness in working-aged adults in developed countries (Moss
et al., 1998; Williams et al., 2004).
Based on clinical observations, it was initially assumed that
microvascular complications only began to develop several years
into the natural history of DM. However, in both the UKPDS
and the Hoorn Study (Spijkerman et al., 2003), about 20% of
the patients had microvascular diabetic complications including
retinopathy, neuropathy, and proteinuria at the time of diagnosis.
These findings raised the question of whether diabetes had been
diagnosed late in this patient cohort or whether microvascular
pathology actually develops during the early stages of DM.
There is now a large body of work showing that the
pathological changes that eventually result in microvascular
complications begin within days to weeks of onset of diabetes.
Clinically, there is evidence of microvascular disease existing
even in the pre-diabetic stage, albeit at a much lower prevalence
than in those who are frankly diabetic (Ford et al., 2010). The
Gutenberg study (Lamparter et al., 2014) revealed a prevalence of
8.2% for DR among the pre-diabetic population in Mid-Western
Germany (7.2% had mild non-proliferative diabetic retinopathy
(NPDR), 0.4% moderate NPDR and 0.2% had severe NPDR).
This figure is in agreement with those from Shanghai where the
prevalence of DR was 8% among pre-diabetics (Zhang et al.,
2009) and also from the Diabetes Prevention Program in the
USA where DR was detected in 7.9% of pre-diabetics (Nathan
et al., 2007). The fact that DR can develop in the pre-diabetic
stage suggests that even the lower levels of glycemia seen in
pre-diabetes are detrimental to the retina.
Intensive treatment of diabetes may reduce the incidence
and severity of DR as shown by the Diabetes Control and
Complications Trial (DCCT) and UK Prospective Diabetes
Study (UKPDS) studies (Diabetes Control Complications Trial
(DCCT) Research Group, 1993; UK Prospective Diabetes Study
Group, 1998). Recently in the FIELD study, it was suggested
treatment of hyperlipidemia may reduce the progression of
diabetic retinopathy and the need for laser treatment (Keech
et al., 2007). However, in practical terms, it is difficult to provide
intensive monitoring to all diabetics given the high prevalence of
DM and the limited resources of any given healthcare system.
At present, effective treatments for DR exist and can prevent
progression to blindness provided the disease is diagnosed early
(Aiello et al., 2001). This highlights the need to develop effective
screeningmethods for DR as identifying those at risk or detecting
disease in its early stages is the key to preventing DR associated
visual impairment.
Currently, formal diagnosis of retinopathy requires
visualization of the retina which in turn requires specialized
resources and specially trained staff. Given limited resources,
there is a need for clinicians to identify the cohort at highest
risk of developing DR and to prioritize screening of this
category of patients. However, at present, there is a lack of
accuracy and specificity in our ability to identify this particular
cohort. There have been several studies analyzing clinical and
demographic characteristics of diabetic patients to identify
risk factors for DR—a systematic review identified duration of
diabetes, hyperglycemia (as measured by HbA1c), hypertension,
hyperlipidemia, pregnancy, and nephropathy/renal disease as
consistent risk factors for diabetic retinopathy (Mohamed et al.,
2007). Less consistent risk factors identified in this review were
obesity, smoking, moderate alcohol consumption, and physical
inactivity. While this information is of great clinical relevance,
these factors will encompass a high percentage of patients and
are not specific enough to truly narrow down the group most
likely to have DR; particularly early stage DR.
At present DR is diagnosed by retinal examination.
Performing retinal examinations on every diabetic patient
represents an enormous logistical challenge, which is further
compounded by the fact that the retina is a notoriously difficult
area to assess accurately in a clinical setting. UK based studies
show sensitivity levels of the detection of sight-threatening
diabetic retinopathy of 41–67% for general practitioners,
48–82% for optometrists, 65% for ophthalmologists, and 27–
67% for diabetologists and hospital physicians using direct
ophthalmoscopy (Torok et al., 2013). Photographic methods
currently use digital images with subsequent grading by trained
individuals and have a sensitivity of 87–100% for the detection
of sight-threatening retinopathy by trained personnel reading
mydriatic 45◦ retinal photographs, with specificities of 83–96%
(Torok et al., 2013). Utilizing photographic methods significantly
increases the ability to correctly identify diabetic eye disease,
however these cameras are costly and gaining access to centers
with this equipment and trained personnel may be a challenge
for the average patient population, especially in developing
countries.
The subjectivity of direct eye assessment—even when
performed by trained personnel—coupled with the limited access
to fundal cameras, highlights the potential clinical benefit in
identifying a biological marker that can accurately diagnose a
patient with DR—particularly early DR—as this could not only
be potentially more accurate but would also facilitate screening
of a much wider segment of the population.
Advances in molecular medicine allowing for rapid
identification of specific biomarkers may be the key to identifying
those at risk of DR and facilitating detection of DR in its early
stages thus allowing for timely intervention. This article aims
to review the various molecular markers associated with the
development of diabetic retinopathy. In particular we aim to
focus on the molecules which show promise as screening tools,
ergo have the capability to detect the disease in its early stages or,
ideally, even before the actual onset of DR.
STAGES OF DIABETIC RETINOPATHY
DR can be classified into two stages: the non-proliferative
phase (NPDR) and the more advanced proliferative phase
(PDR). NPDR is characterized by changes in the retinal
vessels i.e., microaneurysms, intraretinal hemorrhage, venous
beading, and intraretinal microvascular abnormalities. NPDR
is usually asymptomatic, however, left untreated it tends to
progress to PDR which is often accompanied by deterioration
in visual acuity. PDR is characterized by the proliferation of
new vessels (neovascularization) believed to be triggered by
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retinal ischemia which then induces the release of growth
factors including vascular endothelial growth factor (VEGF)
(Giet et al., 2015). Bleeding and leakage from the unstable
new vessels result in tissue alterations causing fibrovasular
epiretinal membranes, vitreous hemorrhage, and tractional
retinal detachment.
The other important component of DR is macular edema
which is the most frequent complication of DR and the most
common cause of vision loss due to diabetes (Cunha-Vaz et al.,
2014). Macular edema is classified as mild, moderate, or severe
based on the distance of the exudates and thickening from the
center of the fovea (Wu et al., 2013).
ANATOMY OF THE RETINA AND
PATHOPHYSIOLOGY OF DIABETIC
RETINOPATHY
Normal Anatomy of the Retina
The retina is the neural layer of the eye, and is essentially an
evagination of the brain consisting of layers of neurons and glial
cells supplied by a rich vascular network from its dual blood
supply from the choroid and the retinal vessels. The retina is
among the most metabolically active tissues in the body making
it highly susceptible to ischemic insults.
The retina contains photoreceptors—specially modified
neurons—which receive light signals from the environment
and convert to them to neural signals which are transmitted to
the visual cortex of the brain via the optic nerve. One of the
unique features of the retina is that it is the only neural tissue
with direct exposure to light, making it susceptible to damage by
photo-oxidized lipids which are highly toxic to the retinal cells
(Simo and Hernandez, 2014).
The photoreceptors of the retina consist of two main types—
the rods and the cones, with the cones being responsible for
color vision. The macula has a very high density of cones and
represents the portion of the retina which is most critical for fine
vision and color vision; and as a result even minor damage to the
macula—e.g., mild macular degeneration—can have significant
impact on visual acuity. The photoreceptors and the supporting
cells known as the glia represent the neural component of the
retina, while the blood vessels that supply the retina represent the
vascular component.
The blood vessels in the retina have unique features necessary
to facilitate the normal functioning of the retina. The most
apparent is the blood retinal barrier (BRB), a particularly tight
and restrictive physiologic barrier that regulates ion, protein, and
water flux into and out of the retina. The BRB consists of inner
and outer components, the inner BRB being formed of tight
junctions between retinal capillary endothelial cells and the outer
BRB of tight junctions between retinal pigment epithelial cells.
The BRB is essential tomaintaining the eye as a privileged site and
is essential for normal visual function (Cunha-Vaz et al., 2011).
An additional unique feature of the retinal blood vessels is the
high density of pericytes, cells which are critical for providing
vascular stability, and control endothelial proliferation (Hammes
et al., 2002).
Overall Pathophysiology of DR
Our current understanding of the pathophysiology of DR
suggests it is highly complex and multifactorial, involving the
activation of several interrelated pathways which all tie in
to several key mechanisms namely increased oxidative stress,
increased pro-inflammatory mediators and increased VEGF
secretion all occurring against a background of the various
metabolic derangements that are inherent to DM (see Figure 1).
DM also results in derangements in neurotransmitters and
neuroprotective factors in the retina. The end result of all these
events is damage to the neural and vascular components of
the retina which eventually give rise to the clinical picture
of DR.
There is evidence to suggest that diabetes results in impaired
normal regulatory mechanisms throughout the neurovascular
complex of the retina very early in the course of diabetes; before
any apparent changes of NPDR are seen—as shown by reduced
vasoconstriction in response to breathing 100% oxygen and
decreased vasodilation in response to flickering light stimulation
(Stem and Gardner, 2013).
Given that the clinical evidence of DR is predominantly
vascular, the initial focus of work on DR focused on the
vascular component; however it has been clearly demonstrated
that the early changes affect the entire neurovascular bundle in
totality, with both components contributing to functional loss.
At present, there is enough information available to suggest
that neural apoptosis precedes overt vascular abnormalities
(Holopigian et al., 1992; Villarroel et al., 2010; Adams and Bearse,
2012; Reis et al., 2014). There is in fact emerging evidence
that neurodegeneration participates in early microvascular
changes that occur in DR such as breakdown of the BRB (via
glutamate mediated excitotoxicity stimulating VEGF release),
vasoregression, and impairment of neurovascular coupling (Simo
and Hernandez, 2014).
Damage to the BRB is a key event in the early pathology of DR.
The central mechanism of altered BRB function is a change in the
permeability characteristics of retinal endothelial cells caused by
elevated levels of growth factors, cytokines, advanced glycation
end products, inflammation, hyperglycemia, and loss of pericytes
(Klaassen et al., 2013).
The effect of all the various interacting pathways
culminates in the eventual end points resulting in DR
namely neurodegeneration, increased vascular permeability,
vascular occlusion, and dysregulated angiogenesis. The
neurodegeneration ultimately results in visual loss. While
the initial triggers are directly a result of the metabolic
derangements inherent to DM, chiefly hyperglycemia, the
subsequent progression of pathology is related to the neuronal
exposure to toxins crossing the damaged BRB and also ischemic
damage as a result of impaired blood supply due to the vascular
occlusion. Ischemia directly results in neuronal damage and
death and the tissue non-perfusion also triggers the release of a
multitude of growth factors which promote angiogenesis—the
defining characteristic of PDR. The degree of cross talk between
the interconnected elements giving rise to the overall picture
of DR make it difficult to truly separate any one event from
another.
Frontiers in Physiology | www.frontiersin.org 3 June 2016 | Volume 7 | Article 200
Pusparajah et al. Molecular Markers of Diabetic Retinopathy
FIGURE 1 | Simplified overview of the multiple interacting pathways leading to the pathogenesis of diabetic retinopathy. Key: PLA2, phospholipase A2;
AA, arachidonic acid; COX2, cyclooxygenase 2; PGE2, prostaglandin E2; AGE, advanced glycation end-products; PKC, protein kinase C; VEGF, vascular endothelial
growth factor; RAS, renin angiotensin system.
Additionally, there appear to be additional factors affecting
the pathogenesis of DR that remain to be defined as even
diabetic patients with similar biochemical profiles may manifest
a wide range of severity of microvasular complications. Cunha-
Vaz et al. (2014) suggest that there are three different phenotypes
of DR designated as A, B, and C where A is a slow progression
type, whereas B and C are more aggressive with B being
characterized by particularly high levels of leakage and C being
characterized by signs of capillary closure. The mechanisms
underlying the possible predominance of various pathways in
different phenotypes remains to be defined.
Recently there has been great interest in exploring the role of
microRNA (miRNA) in the etiology of DR. miRNAs are small,
noncoding RNAs that represent a newly recognized, important
level of gene-expression regulation that act post-transcriptionally
to modulate expression of target genes via inhibition of protein
expression by interfering with the translation and/or stability or
mRNA (Cowan et al., 2014; Joglekar et al., 2016). To date, it is
estimated that the entire human genome encodes for about 1100
miRNAs able to modulate the expression of about 60% of the
protein-coding genes (Mastropasqua et al., 2014). miRNAs play
important roles in diabetes and its complications as they regulate
multiple biological pathways closely related to DR (Kovacs et al.,
2011).
Hyperglycemia and Oxidative Stress in DR
The key underlying element underpinning the core
pathophysiology of DR appears to be hyperglycemia. The
key role of hyperglycemia in triggering intracellular metabolic
pathways that cause diabetic complications can also be inferred
from the fact that diabetes selectively damages cells whose
glucose transport rate does not decline rapidly as a result of
hyperglycemia.
One of the key unifying mechanisms of hyperglycemia’s effects
is increased oxidative stress via increased superoxide production
through the mitochondrial electron chain (Brownlee, 2005). This
is believed to be the upstream event leading to increased flux
through the polyol pathway, increased intracellular production
of AGE precursors, increased PKC activation, and increased
hexosamine pathway activity. Activation of these pathways then
triggers increased production of pro-inflammatory substances
through various other pathways. The effects of oxidative
stress in diabetics are exacerbated by decreased levels of
reducing substances—one of the mechanisms underlying this
is increased flux through the polyol pathway which involves
the NAPDH consuming generation of sorbitol from glucose
via the action of aldose reductase, which in turn results in
decreased levels of reduced glutathione rendering the cell
more vulnerable to oxidative damage. Hyperglycemia mediated
oxidative stress appears to be one of the linking factor between
neurodegeneration and early microvascular abnormalities (Stem
and Gardner, 2013).
Other pathways that have been implicated as potential links
between hyperglycemia and DR include activation of growth
factors such as vascular endothelial factor (VEGF) and insulin-
like growth factor (IGF-1) and hemodynamic changes causing
activation of the renin-aldosterone-angiotensin system (RAAS)
(Tarr et al., 2013).
Inflammation in DR
Current evidence suggests inflammation is one of the key
players underpinning the pathological changes of DR. Chronic,
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low-grade subclinical inflammation is responsible formany of the
signature vascular lesions of DR (Joussen et al., 2004). Clinical
evidence proving this link was provided by the Hoorn Study, a
population—based cohort study which recruited 625 patients and
found that the prevalence of retinopathy was positively associated
with tertiles of C reactive protein (CRP) and soluble intercellular
cell adhesion molecule 1 (sICAM-1) (Van Hecke et al., 2005).
The characteristic low-grade chronic inflammation in diabetes
is the result of the expression and production of numerous
inflammatory markers including pro-inflammatory cytokines
such as tumor necrosis factor alpha (TNFα), interleukin 1
(IL1), interleukin 6 (IL6), interleukin 8 (IL8), CRP, monocyte
chemoattractant protein 1 (MCP1) as well as E-selectin and
adhesion molecules such as intracellular adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1).
Soluble forms of VCAM-1 and ICAM-1 designated sVCAM-
1 and sICAM-1 are released from activated endothelial cells
and control leukocyte activation and their migration to the
site of inflammation. Elevated circulating and vitreous levels
of sVCAM-1 have been demonstrated in patients with PDR
(Kaul et al., 2010) and hyperglycemia has been shown to
induce significant increase in expression of interleukin-1β (IL-
1β), transmembrane receptors IL-1RI, and IL-RII as well as the
natural antagonist receptor IL-1Ra (Scuderi et al., 2015). Reduced
levels of lipoxin A4 (LXA4), a key mediator of the resolution
of inflammation have been demonstrated in patients with DR
(Kaviarasan et al., 2015). As illustrated in Figure 1, there are
multiple pathways that lead to the increased production of these
pro-inflammatory mediators.
One of the suggested mechanisms for the proinflammatory
state in DM is the activation of toll like receptors (TLR)
two and four which are activated by the hyperglycemia
induced oxidative stress. It has been demonstrated that
inflammation in hyperglycemic human retinal endothelial
cells was attenuated by inhibition of TLR-4 and TLR-2
(Rajamani and Jialal, 2014).
A central and causal role of adherent leukocytes in vascular
damage in DR—which is related to an increased expression of
ICAM 1 and CD 18—results in increased numbers of leukocytes
in retinal vasculature of diabetic humans and in animal work has
been shown to begin as early as 1 week following experimental
diabetes onset and results in injury to the endothelium via a
Fas ligand (FasL)—mediated mechanism; a process which leads
to breakdown of the BRB (Joussen et al., 2004). The presence
of chronic inflammation also promotes increased production of
VEGF which increases vascular permeability and later promotes
angiogenesis.
Cyclooxygenase 2 (COX-2) is one of the key enzymes in
the inflammatory cascade given its role in the production of
prostaglandins (PGs) from arachidonic acid. COX-2 levels have
been shown to be upregulated in diabetes via the PKC pathway
following increased hyperglycemia-induced mitochondrial ROS
production (Kiritoshi et al., 2003). An additional role for COX-
2 as a modulator for angiogenesis via interaction with the
VEGF pathway has been proposed with one possible route being
an exciting new pathway, the ERK1-2/COX-2/PGE2 pathway
which has been postulated as a signaling pathway mediating
GPR-91 dependent VEGF release and thus contributing to the
development of DR (Li et al., 2014).
Phopholipase A2 (PLA2), also a key enzyme in the
inflammatory cascade, has been shown to be upregulated under
conditions of hyperglycemia. Data indicates that high glucose
directly damages pericytes through activation of PLA2/COX-
2/VEGF-A pathway (Giurdanella et al., 2015). PLA2 releases
arachidonic acid (AA) from phospholipids; with AA being the
precursor of prostaglandins. Overall, data suggest that PLA2 are
involved in BRB breakdown during the early stages of DR, by a
mechanism involving the up-regulation of COXs, PG synthesis,
VEGF, ICAM-1, and TNFα (Lupo et al., 2013).
Increased production of pro-inflammatory mediators is also
triggered by interaction between Advanced Glycation End
Products (AGE) and their receptors (R-AGE). The increased
production of AGE in diabetics increases AGE-RAGE interaction
which in turn activates the production of pro-inflammatory
cytokines further contributing to the inflammatory state (Stem
and Gardner, 2013).
VEGF and Its Role in DR
VEGF is best known as a pro-angiogenic factor promoting
the growth of new vessels in the proliferative phase of DR;
and elevated VEGF levels in the vitreous are one of hallmark
features of PDR. However, elevated levels of VEGF have been
demonstrated in earlier stages of diabetic eye disease, suggesting
that it may have other roles in the pathogenesis of DR. VEGF
is currently thought to play a crucial role in pathogenesis of
DR—causing breakdown of the blood-retinal barrier, stimulating
endothelial cell growth and neovascularization, and increasing
vascular permeability in the ischemic retina. The amount and
duration of VEGF exposure required for BRB breakdown is less
than that required for neovascularization (Jain et al., 2013). VEGF
is also a proinflammatory molecule whose vitreal levels are highly
correlated with retinal, neovascularization and edema (Tang and
Kern, 2011).
There are many novel pathways leading to increased VEGF
secretion which have been characterized providing new insight
into the molecular mechanisms underlying the changes of DR
which in turn provides exciting new possibilities for therapeutic
targets as well as potentially pointing the way to new potential
markers worth screening for to detect DR.
Amadio et al. (2010) described a PKCβ/HuR/VEGF pathway
which is postulated to have a role in the pathophysiology of
DR. PKC is a family of at least 10 serine-threonine kinases
ubiquitously expressed and able to participate in multiple cellular
functions. PKC β is the PKC isoenzyme preferentially activated in
the eye. HuR is the ubiquitously expressed member of the ELAV
(embryonic lethal abnormal vision) family, highly conserved
mRNA binding proteins which act post-transcriptionally as
positive regulators of gene expression which appears to protect
VEGF mRNA from ribonucleases as well as enhancing its
translation. This pathway was initially explored in vitro in
retinal pericytes (Amadio et al., 2008) and subsequently in
Sprague-Dawley rats (Amadio et al., 2010) and it was found
that PKCβ/HuR activation was accompanied by enhanced VEGF
protein expression that was blunted by a PKCβ inhibitor.
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Genetic deletion of COX-2 diminished VEGF production
in mouse retinal Muller cells (Yanni et al., 2010). One
potential pathway by which this effect could be mediated is
the recently described ERK1/2/COX-2/PGE2 pathway described
earlier (Section Inflammation in DR).
An additional pathway increasingVEGF levels inDMcould be
the renin-angiotensin pathway which is upregulated in diabetic
patients. Angiotensin II has been shown to have a positive effect
on the secretion of VEGF (Wilkinson-Berka, 2006).
Ischemia is of course one of the strongest triggers for
VEGF secretion and once vascular damage and occlusion
lead to significant areas of tissue non-perfusion, this triggers
increasingly elevated secretion of VEGF which then triggers
angiogenesis.
AGEs in Pathology of DR
Advanced Glycation End Products (AGEs) are acknowledged
to have a central role in the pathogenesis of the vascular
complications of diabetes including DR (Kandarakis et al., 2014).
AGEs are actually a complex group of compounds formed via
a nonenzymatic reaction between reducing sugars and amine
residues on proteins, lipids or nucleic acids. The role of AGEs in
the pathobiology of DR has been demonstrated by vitreous work
demonstrating increased levels in advanced disease (Nakamura
et al., 2003; Pachydaki et al., 2006; Kakehashi et al., 2008).
Glycation of proteins interferes with their normal functions by
disrupting molecular conformation, altering enzymatic activity,
and interfering with receptor functioning. AGEs form intra- and
extra-cellular cross linking not only with proteins, but with some
other endogenous key molecules including lipids and nucleic
acids to contribute to the development of diabetic complications.
Hyperglycemia upregulates intracellular formation of AGEs,
with the most abundant AGE present being carboxymethyllysine
(CML) the levels of which have been suggested to be associated
with incidence of diabetic complications (Li et al., 2012).
Pentosidine is one of the other well-defined AGE products
to date—it is synthesized through nonenzymatic reactions of
pentose and its formation is closely related to oxidative processes.
Increasing levels of plasma pentosidine have previously been
linked to increased vascular rigidity of the retinal arteries in
patients with type 2 diabetes with retinopathy (Sato et al., 2012).
In addition to the cross linking effect, AGEs exert their
effects via binding to receptors for AGE (RAGE) which are
expressed by several cells. AGE-RAGE interaction has clearly
been demonstrated to be involved in the development of
microvascular complications. However, in addition to cell bound
RAGE, there are soluble forms in the plasma with soluble RAGE
(sRAGE) representing a proteolytically cleaved form of RAGE,
the role of which is much less well-defined. They may reflect the
activity of the AGE-RAGE axis (Kerkeni et al., 2012) while other
work suggests that they be inhibitors of AGE-RAGE mediated
pathological effects (Grossin et al., 2008).
Metabolic Changes of Diabetes and DR
Other links in the pathogenesis of DR related to metabolic
derangements found in DM include elevated homocysteine
(Malaguarnera et al., 2014) and lipoprotein a (Malaguarnera
et al., 2013) levels. Reduced folate levels seen in diabetics
have been found to be associated with an increased rate
of DR (Malaguarnera et al., 2015). The pathways again are
interlinked, however at present, reduced folate is believed
to play a role via impaired nitric oxide production and
impaired methylation ability resulting in DNA damage. The
reduced folate levels also contribute to elevated homocysteine
levels, where homocysteine is toxic to vascular endothelium
and therefore induces thrombosis and contributes to
ischemia.
DM is strongly associated with dyslipidemia and it has been
demonstrated that atherogenic lipoproteins are associated with
progression of retinopathy. Serum levels of lipoprotein (a) or
Lp(a), an LDL like molecule, have been demonstrated to be
elevated in patients with DR. One possible explanation for the
connection between Lp(a) and DR is that Lp(a) induces a pro-
thrombotic state by reducing fibrinolytic activity in the blood
circulation (Malaguarnera et al., 2013).
Altered Levels of Neurotransmitter and
Neuroprotective Factors
The most important mechanisms in the neurodegenerative
process are extracellular glutamate accumulation, oxidative stress
(see Section Hyperglycemia and Oxidative Stress in DR), and
reduction of neuroprotective factors synthesized by the retina.
Glutamate, the major excitatory neurotransmitter in the
retina, has been found to be elevated in the extracellular space of
the retina of experimental animals with diabetes. The glutamate
excess results in excitotoxicity due overactivation of AMPA and
NMDA receptors which then causes uncontrolled intracellular
calcium response and ultimately cell death. Glutamate toxicity
also contributes to glutathione depletion, contributing further to
oxidative stress (Simo and Hernandez, 2014).
There are reports of reduced synthesis of several
neuroprotective factors such as pigment epithelial-derived
factor (PEDF), brain derived neurotrophic factor (BDNF),
nerve growth factor (NGF), somatostatin (SST), and interstitial
retinol-binding protein (IRBP) in the retina of diabetic patients
compared with non-diabetic subjects (Stem and Gardner, 2013;
Simo and Hernandez, 2014).
BDNF is a member of the neurotrophin family of
growth factors and is important in the development,
differentiation and maintenance of neurons. BDNF has
been shown to inhibit apoptosis in rat retinal ganglion cells
at early stages of DR and it has been shown that BDNF
protects retinal neurons from hyperglycemia through the
Tropomyosin-related kinase B (TrkB)/ERK/MAPK pathway
(Liu et al., 2013).
Aside from its neuroprotective function, Pigment Epithelium-
Derived Factor (PEDF) is also a potent anti-angiogenic factor
(Dawson et al., 1999) with low PEDF levels predisposing to
pathologic angiogenesis. Evidence comes from animal work in
mice where treatment with PEDF inhibited retinal microvascular
dysfunction (Longeras et al., 2012; Ibrahim et al., 2015) and
enhanced survival of retinal ganglion cells (Unterlauft et al.,
2014).
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MARKERS OF DIABETIC RETINOPATHY
There have been a large number of studies looking for a reliable
biomarker of DR. Given that an ideal screening sample needs
to be easily obtainable, blood markers (as opposed to vitreous)
are the obvious choice as a blood sample is an easily obtained
specimen with good acceptability rate among the typical patient
population. Other samples that have studied with screening
potential include skin biopsies and more recently tear fluid. This
article does not aim to be an exhaustive review of all markers
previously analyzed but focuses on those with greater potential
as clinical markers of disease risk and progression. We therefore
aimed to include work that looks at a spectrum of DR from mild
to severe disease rather than those that only recruited patients
with PDR. This was done as a useful screening marker would
need to be a substance that shows elevated levels from early
disease with a significant difference between the levels in diabetic
patients without DR (NDR) and NPDR patients; an ideal marker
should also show an increasing level with progressive disease
severity as this would allow an estimation of disease severity and
urgency of referral.
The studies selected for review have been divided into
categories based on the substances analyzed namely AGEs,
VEGF, inflammatory markers, and other proteins of various
categories. The studies are summarized in Tables 1–5. Recent
work looking for novel proteins via proteomics technology is
also considered as well as miRNA which appears to have great
promise as a biomarker. Although there is a fairly large body of
work in the literature, it is largely limited by virtue of the fact
that most are relatively small scale single center studies utilizing
a cross sectional study design. Only two large scale prospective
studies were found both of which were part of the work from the
DCCT trial in the UK.
Advanced Glycation End-Products (AGEs;
Table 1)
As shown in Table 1, various AGEs have been analyzed as
potential biomarkers of DR, with one of the key AGEs of interest
being carboxymethyllysine (CML) which has been demonstrated
to be elevated in the serum of patients with diabetic retinopathy
(Boehm et al., 2004; Mishra et al., 2015). Significant differences
were found in serum levels of N-epsilon carboxymethyl lysine
between healthy controls and diabetics both with and without eye
disease as well as increasing with progressive severity of DR.
Mishra et al. (2015) analyzed N-epsilon-CML (Nε- CML)
in a total of 80 subjects—20 healthy controls and 60 diabetic
patients (20 NDR, 20 with NPDR, 20 with PDR). Nε- CML levels
increased with disease severity and were significantly different
between all 4 groups (p < 0.001) and the levels also showed
statistically significant correlation with the degree of disruption
of the external limiting membrane (ELM) (p< 0.001). Univariate
analysis with fasting blood glucose levels and HbA1c showed
Nε- CML was an independent predictor of retinopathy. This
seems to suggest it would be a good target for future work as it
appears to show elevated levels from early disease compared to
those without DR and increases with progressive disease severity
allowing for estimation of urgency for treatment.
Mishra’s findings were largely in agreement with earlier work
which also found Nε- CML to be a promising marker of DR
(Choudhuri et al., 2013). This study recruited a total of 379
subjects (95 healthy controls (HC), 102 NDR, 70 with NPDR,
and 105 with PDR). They found that there was a statistically
significant difference in serum Nε-CML levels between all four
groups (HC vs. NDR p= 0.02; NDR vs. NPDR p< 0.001; NPDR
vs. PDR p = 0.017). One intriguing finding here was that the
level of Nε-CML was actually higher in NPDR compared to PDR
and this was statistically significant. This was considered to be an
indication that Nε-CML has pathogenic implications for retinal
microvascular function in the earlier stages of DR. Choudhuri
et al. (2013) also measured total serum AGE levels and though
there was no significant difference between NPDR and PDR
groups (p=−0.2643), there was a significant difference between
theNDR andNPDR groups (p= 0.0297). This suggests that while
serum AGE may not be a definitive marker of the severity of DR,
it may be a promising marker of the presence of DR as an overall
entity. In patients with NPDR and PDR there was a correlation
between the serum levels of AGEs and Nε-CML, but this was not
true in healthy controls and diabetics with no retinopathy.
Serum levels of Nε- CML in DR were also assessed in a
case-control study which showed that high serum levels of
CMLwere associated with proliferative retinopathy and clinically
significant macular oedema (Boehm et al., 2004). This study had
relatively few patients with eye disease but a very large cohort
of controls whereby they recruited 56 patients with T2DM with
DR, 81 diabetic patients with no DR, and 792 healthy controls.
One limitation of this study from the perspective of potential
screening markers is that even though the patients who were
examined were classified according to ETDRS criteria into NPDR
and PDR the results appear to have been analyzed collectively
with the DR cohort consisting of both PDR and NPDR. The data
from this trial showed that serum CML levels were significantly
higher in DR group compared to controls (p < 0.0001) and that
the levels were independent of HbA1c.
Prospective trials are always of particular interest and CML
levels from skin biopsy were found to be a predictor of new
occurence and progression of retinopathy in diabetic patients
based on work by the DCCT team (Genuth et al., 2005). This
trial was a prospective trial using patients enrolled in the DCCT
study and showed that elevated levels of furosine (glycated
collagen) and CML in skin and collagen were predictive of
risk of future DR. This study looked at skin biopsies obtained
from 211 patients in the DCCT trial ∼1 year before the
trial ended, and followed up this cohort for 10 years looking
for development of or progression of existing retinopathy. In
multivariate analyses, a combination of furosine and CML
predicted the progression of retinopathy (χ2 = 59.4, p< 0.0001);
even after adjustment for HbA1c (χ2 = 32.7, p < 0.0001).
This trial also clearly demonstrated that the glycated proteins
and AGE levels in skin was independent from HbA1c as a
predictor of risk of progression of microvascular disease. The
ability to predict those at high risk of disease even prior to disease
onset would be make this an ideal marker to target those at
increased need for intensive control and closer monitoring for
complications.
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TABLE 1 | Summary of selected studies analyzing levels of AGEs in association with presence of varying stages of diabetic retinopathy.
Subtance(s)
analyzed
Reference/study
design
Patient population Key findings Method of analysis
AGEs, sRAGE,
and pentosidine
(serum)
Kerkeni et al.,
2012/cross
sectional
N = 130 (40 NPDR, 60
PDR, 30 healthy controls)
Serum AGEs, sRAGE, and
pentosidine levels significantly higher
in patients with PDR vs. NPDR
(p = 0.001, p = 0.01, and p = 0.005)
ELISA (Abo Switzerland Co. Ltd)
no comparison against diabetics with
no eye disease
Furosine (glycated
collaged) and CML
(skin biopsy)
Genuth et al.,
2005/prospective
N = 216 (65 NDR
baseline, 57 with baseline
mild to mod DR or
microalbuminuria) + 40
age matched healthy
controls
Furosine + CML predicted
progression of retinopathy
independent of HbA1c (χ2 = 59.4, p
< 0.0001)
HPLC of prepared skin biopsy
specimens
hydroimidazole
(methylglyoxal
derived AGE)
(serum)
Fosmark et al.,
2006/cross
sectional
N = 227 (89 NPDR, 52
PDR, 86 no DR)
Serum levels of hydroimidizole higher
in PDR vs. NDR (p = 0.002);
significant increase in NPDR vs. NDR
(p = 0.008)
Specific solid-phase,
time-resolved competitive
immunoassays (Delfia Wallac,
Turku, Finland)
Nε-CML (serum) Boehm et al.,
2004/case control
N = 929 (81 NDR, 56
NPDR, 792 healthy
controls)
Serum CML provided progressive risk
marker for PDR (OR
24.5)independent of HbA1c; serum
CML >1000 ng/ml strongly related to
presence of clinically significant
Competition based ELISA
(mouse monoclonal 4G9; Alteon,
ramsey, NJ, USA)
macular edema; serum CML levels
elevated in DR vs. controls (p <
0.0001)
N-epsilon-CML
(Nε-CML) (serum)
Mishra et al.,
2015/cross
sectional
N = 80 (20 NDR, 20
NPDR, and 20 PDR, 20
healthy controls)
Mean levels of Nε-CML increased
significantly with increasing severity of
DR (p < 0.001 between controls,
diabetics with no eye disease, NPDR,
and PDR, respectively)
ELISA (Human Nε-CML ELISA kit
from Uscn, Life Science Inc,
USA)
N-epsilon-CML
(Nε-CML) (serum)
Choudhuri et al.,
2013/cross
sectional
N = 379 (102 NDR, 77
NPDR, 105 PDR, 95
healthy controls)
Significant elevation of serum AGEs
and Nε-CML in subjects with PDR (0
< 0.0001) and NPDR (p < 0.0001)
compared to NDR
Nε-CML: ELISA (Cell Biolabs
kit(catalog No STA 316)
AGEs (serum) AGEs: ELISA(Cell Biolabs,
SanDiego, CA) (kit no STA 317)
N-CML and
pentosidine
(serum)
Hirata and Kubo,
2004/cross
sectional
N = 97 diabetic patients
(42 NDR, 18 NPDR, 37
PDR)
Significantly higher blood levels of
CML and pentosodine in PDR group
compared to NDR (p < 0.01 and p <
0.05, respectively), no significant
difference in CML or pentosidine
levels between no DR and NPDR or
between NPDR and PDR.
ELISA (assays prepared in own
lab)
sRAGE and
pentosidine
(plasma)
Ng et al.,
2013/cross
sectional
N = 606 (171 NDR, 200
with DR (125 with NPDR;
75 with PDR), 235
healthy controls)
sRAGE/pentosidine ratio in DR
patients was significantly lower than
the ratio in diabetics without DR (p <
0.001); l higher levels of pentosidine,
sRAGE, and sRAGE/pentosidine ratio
in PDR compared to NPDR (p < 0.05,
0 < 0.01, and P < 0.01, respectively)
Standard ELISA sandwich kit:
pentosidine (USCNK Life
Scinece Inc, Wu Han, China);
sRAGE (Biovendor Laboratorni
Medicina akciova spolecnost,
Brno, Reckovice, Czech
Republic)
CML, carboxymethyl-lysine; sRAGE, soluble receptors for advanced glycation end-products; NDR, diabetic with no retinopathy, NPDR, non-proliferative diabetic retinopathy; PDR,
proliferative diabetic retinopathy.
Other studies assessing serum levels of methylglyoxal-derived
hydroimidazole (an AGE) found the serum levels were raised in
diabetic patients with retinopathy vs. those with no retinopathy
(Fosmark et al., 2006). This cross sectional study recruited a
reasonably large pool of patients—227 subjects with T2DM and
various stages of DR (89 with NPDR, 62 with PDR and 86
NDR). The levels of serum hydroimidazole were on aggregate
higher in the PDR compared to the NPDR group but the
article did not attempt to analyze its ability to differentiate
the different stages of DR. There was a statistically significant
increase in hydroimidazole levels in DR compared to those with
no DR (NPDR p = 0.008, PDR p = 0.002). While DR did
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TABLE 2 | Summary of selected studies analyzing levels of Vascular Endothelial Growth Factor (VEGF) in association with presence of varying stages of
diabetic retinopathy.
Sample
analyzed
Study design Sample size Key findings Method of analysis
VEGF
(plasma)
Cavusoglu et al., 2007/Cross
sectional
N = 83 (31 NPDR, 34 PDR,18
healthy controls)
VEGF levels increased significantly
between NPDR and PDR (P = 0.016)
and also between diabetics with NPDR
vs. healthy controls (p < 0.000) as well
as between PDR and healthy controls
(p < 0.000)
ELISA (Biosource) sensitive to
VEGF-165
VEGF (serum) Du et al., 2014/Cross sectional
(see also Table 4)
N = 69 diabetic patients (30
NDR, 23 NPDR, 16 PDR)
Increasing serum VEGF trend between
no DR, NPDR and PDR groups; higher
levels of VEGF in PDR vs. NPDR and
NDR (p = 0.007 and p < 0.001,
respectively); VEGF levels in NPDR vs.
NDR also significantly higher (p = 0.007)
ELISA (human VEGF ELISA kit,
Rapid Bio Lab, Calabasas, CA,
USA)
VEGF (serum) Jain et al., 2013/cross
sectional
N = 77 (19 NDR, 19 NPDR,
20 PDR, 19 healthy controls)
VEGF levels were significantly different
between the study groups (p < 0.001)
by ANOVA
Human VEGF ELISA kit, Invitrogen
VEGF (serum) Ozturk et al., 2009/cross
sectional
N = 156 (31 NDR, 49 NPDR,
46 PDR, 28 healthy controls)
VEGF levels higher in those with NPDR
compared to controls (p = 0.01), and in
PDR compared to controls (p = 0.02).
No significant difference between NPDR
and PDR (p = 0.87)
Luminex multiplex bead
immunoassay (Human Cytokine
LINCOplex kit; LINCO Research,
St Charles, MO)
VEGF, Vascular Endothelial Growth Factor; NDR, diabetic with no retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.
correlate with HbA1c, the results showed that the serum levels
of hydroimidazole were independent of the HbA1c. Multiple
regression analysis showed a significant association between
serum hydroimidazole levels and DR (OR = 1.45, p = 0.04).
Given that there is a significant difference between controls and
NPDR, this would also constitute a potential marker, however
Nε-CML, having been found to be the prevalent AGE, appears
to be a more promising target as a clinical marker.
Serum AGEs, sRAGE, and pentosidine levels in relation to
severity of DR were analyzed in a study of 40 NPDR patients,
60 PDR patients, and 30 healthy controls (Kerkeni et al., 2012).
However, this study did not include a group of diabetics with
no eye disease making it difficult to comment on the ability
of these substances to differentiate between a diabetic with
and without eye disease. Overall the study found that all the
substances analyzed showed significantly higher levels in PDR
compared to NPDR, with AGE, sRAGE and pentosidine having
significance levels of p = 0.001, p = 0.01, and p = 0.005,
respectively.
Pentosidine has also been the focus of several studies, often
in combination with CML. While it has been demonstrated to
be increased in the serum of patients with DR, overall it appears
less sensitive than CML in detection of DR (Hirata and Kubo,
2004; Kerkeni et al., 2012). Hirata and Kubo analyzed 97 diabetic
patients—42 without eye disease (NDR), 18 with NPDR and
37 with PDR. CML and pentosidine levels were independent of
HbA1c. There was no significant difference between either the
CML or pentosidine levels between NDR and NPDR groups.
The difference was only significant between NDR and PDR
groups with p < 0.01 and p < 0.05 for CML and pentosidine,
respectively. Again, this makes these markers less likely to detect
early stage DR.
Recent work suggests that sRAGE/pentosidine ratio could be
a risk factor determinant for DR (Ng et al., 2013). This study
recruited 606 subjects (171 NDR, 125 with NPDR, 75 with
PDR, and 235 healthy controls). The findings did not show
a consistent elevation in either pentosidine in patients with
DR versus diabetics without retinopathy. The levels of sRAGE
were elevated in DR, and were statistically significant between
combined NPDR and PDR against healthy diabetics without eye
disease and PDR vs. NPDR but not for NPDR alone compared
to NDR. When compared with diabetics without eye disease.
sRAGE/pentosidine ratio was also analyzed and found to show
a consistent upward trend with severity of DR, and a significant
difference was found between all patients with DR even on
multiple logistic regression (p= 0.048); however again there was
no significant difference between NDR and NPDR groups.
Based on the work done so far, Nε-CML appears to be the AGE
with the most potential as a screening marker for DR particularly
with regard to being able to predict risk of developing DR in
newly diagnosed diabetics.
VEGF (Table 2)
VEGF is currently implicated as a mediator of NPDR and
an initiator of PDR. VEGF has been widely studied and is
postulated to have multiple roles in the pathogenesis of DR
making it a logical target as a marker and the work done
so far seems to support its potential in this light. A positive
correlation between serum levels of VEGF and the incidence
of DR (Ozturk et al., 2009) with the VEGF levels correlating
with the stage of retinopathy (Cavusoglu et al., 2007) have been
demonstrated.
A cross sectional analysis of 69 diabetic patients (30 NDR,
23 NPDR, and 16 PDR), were able to show an increasing
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TABLE 3 | Summary of selected studies analyzing levels of inflammatory markers in association with presence of varying stages of diabetic retinopathy.
Substance(s) analyzed Reference/study
design
Patient population Key findings Method of analysis
α2- anti plasmin, fibrinogen,
plasminogen, PAI-1 (plasma)
Polat et al., 2014/cross
sectional
N = 52 (21 NDR, 18 NPDR,
13 PDR, 40 healthy controls)
Significantly elevated levels of α2-anti
plasmin in diabetics, with significant
elevation with increasing severity of eye
disease: p < 0.005 for NPDR and p <
0.001 for PDR
α2-anti plasmin,
plasminogen:ELISA
(Cusabio Biotech Co Ltd)
PAI-1 levels were higher in diabetics
compared to non-diabetics but did not
reach significance (p = 0.209)
PAI-1: ELISA (Border Med
System, Vienna)
Fibrinogen and plasminogen levels were
similar between diabetics and controls.
Fibrinogen: ELISA (MTI
Tokyo)
hs CRP (serum) Sasongko et al.,
2014/cross sectional
N = 224 (23 NDR, 144 with
mild to moderate NPDR
(non-vision threatening), 57
with severe NPDR or PDR
(vision threatening)
Statistically significant increase in hsCRP
level in vision threatening vs. non-vision
threatening DR (OR 1.3 in multiple
regression model, 95% CI 1.1-1.5)
hsCRP: Nephelometry
(Nephelometer; Siemens
Healthcare Diagnostics Inc,
Newart, DE, USA)
sICAM-1,
VCAM-1,E-selectin,
endothelin -1, total nitrite
No correlation between serum markers of
endothelial function and DR severity
All others: ELISA (R&D
systems, Minneapolis, MN,
USA)
ICAM-1 (intercellular
adhesion molecule-1)
(serum)
Jain et al., 2013/cross
sectional
N = 77 (19 NDR, 19 NPDR,
20 PDR, 19 healthy controls)
ICAM-1 levels were significantly different
between the study groups (p < 0.001)
Human sICAM-1 ELISA kit,
Invitrogen
NO, sIL2R, IL 8 and TNF α
(serum)
Doganay et al.,
2002/cross sectional
N = 67 (15 NDR, 18 NPDR,
19 PDR, 15 healthy controls)
Statistically significant elevation of NO,
sIL2R, IL 8, and TNF alpha between
NPDR vs. no DR and controls (p < 0.01);
and also between PDR vs. NPDR, no DR,
and controls (p < 0.001). no statistically
significant difference between controls and
DM with no DR (p > 0.05)
Cytokines and chemokines:
Chemiluminescent
immunometric assay
(Immulite, Diagnostic
Products, Los Angeles); NO
via spectrophotometric
quantitation using Griess
reagent
PTX3, hsCRP (plasma) Yang et al.,
2014/case-control
N = 163 (30 NDR, 28 mild
NPDR, 21 moderate NPDR,
23 severe NPDR, 20 PDR,
41 healthy controls)
Proportion of higher-degree retinal
complications increased in direct
correlation with log PTX3 levels (p trend <
0.001) vs. log hs-CRP-values P trend <
0.006. ROC curves for PTX3 show
diagnostic sensitivity for DR 53.3%,
specifiticy 91.7 vs. 51.1% and 70.8% for
hs-CRP)
PTX3: ELISA (R&D Systems
IC, Minneapolis, MN, USA);
hs CRP; ELISA
(DakoCytomation,
Copenhagen, Denmark;
human hsCPR standards
from Randox Laboratories,
Count Antrim, UK)
RANTES, SDF-1α (serum) Meleth et al., 2005/cross
sectional
N = 93 (62 less severe DR,
31 severe NPDR or worse)
Significant elevation between at least
severe NPDR vs. less severe DR: RANTES
(p < 0.001) and SDF-1α (p < 0.007)
ELISA (R&D Systems Inc,
Minneapolis, MN)
sE-selectin, PAI 1 (serum) Rajab et al.,
2015/prospective
N = 1391 diabetic patients
with either mild or moderate
retinopathy or no DR at
baseline (260 progressed to
severe NPDR and 831
progressed three steps in
severity of DR)
High levels of sE selectin and PAI 1 at
baseline are associated with development
of retinopathy in patents who had no
retinopathy at baseline. Increased levels of
PAI 1 correlated with risk of progression to
severe pre-proliferative or PDR
Signature Plus Protein Array
imaging and Analysis
System (Aushon
BioSystems) uwing Array
VisionTM software for data
analysis
NO, nitric oxide; sICAM-1, soluble intercell adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; sIL2R, Soluble interleukin-2 receptor; IL-8, interleukin-8; tumor necrosis
factor alpha (TNF α); RANTES, Regulated on Activation, Normal T-cell Expressed and Secreted; SDF-1α, stromal derived factor-1α; sE-selectin, soluble-E-selectin; PAI 1, plasminogen
activator inhibitor 1; hs CRP, high sensitivity C-reactive protein; PTX 3, pentraxin 3; NDR, diabetic with no retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative
diabetic retinopathy; ROC, receiver operating curve.
serum VEGF trend with increasing severity of DR, with
a statistically significant difference between NDR vs. NPDR
(p = 0.007) which would suggest it does have potential as a
screening marker. (Du et al., 2014) However, these findings
are not consistently replicated by the other studies in the
literature.
Jain et al. (2013) analyzed serum VEGF levels in 19 patients
with NPDR and 20 patients with PDR and compared them
against 19 diabetics with no eye disease and 19 healthy controls.
There was a significant elevation in VEGF with progressive
severity of retinopathy (OR 3.98, CI 95%). ANOVA showed
statistically significant differences between all groups (p< 0.001)
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TABLE 4 | Summary of selected studies analyzing levels of other markers in association with presence of varying stages of diabetic retinopathy.
Substance
analyzed
Reference/Study method Patient population Key findings Method of analysis
Apelin 13
(serum)
Du et al., 2014 /cross
sectional (see also Table 2)
N = 69 (30 NDR, 23 NPDR,
16 PDR)
Significant elevation in serum apelin between PDR
and no DR (p = 0.041); no significant difference in
levels between NPDR and no DR group
ELISA (human apelin-13
ELISA kit; Uscnlife Science
and Technology Company,
Missouri)
BDNF (serum) Kaviarasan et al., 2015/cross
sectional
N = 114 (27 NDR, 30
NPDR, 30 PDR and 27
healthy controls)
Significantly lower serum in both NPDR and PDR
compared to healthy controls for BDNF
(p = 0.0071, p = 0.0075)and LXA4 (p = 0.020,
p = 0.008); BDNF and LXA4 levels shows
progressive drop as seen in median across no
DR, NPDR, and DR groups.
BDNF: ELISA (Chemikine)
LXA4 (plasma) IL-6 significantly increased in NPDR and PDR
compared to healthy controls. Other cytokines no
significant increase.
LXA4: ELISA (Oxford)
IFN-γ, TNF-α,
IL-10, IL-6.IL-4,
IL-2
Cytokines: cytometric bead
array system (BD
Biosciences, Germany)
Chemerin
(serum)
Du et al., 2016/cross
sectional
N = 80 (25 NDR, 20 NPDR,
15 PDR, 20 healthy controls)
Serum chemerin levels showed statistically
significant increase with increasingly severe eye
disease; trend chi square for chemerin level vs.
sensitivity of DR χ2 = 16.07, p < 0.001
ELISA (human Chemerin
ELISA kit, Uscnlife Science
and Technology Company,
Missouri, TX)
Lipoprotein (a)
[Lp(a)] (Serum)
Malaguarnera et al.,
2013/cross sectional
N = 145 (78 NDR, 67 DR) Elevated Lp(a) levels were found in 78.3% of
patients with DR but only in 21.75% of diabetic
patients with no DR
Immunonephelometry
(Olympus AU640 Medican
Watford, UK)
Folate (plasma,
red cell folate)
Malaguarnera et al.,
2015/cross sectional
N = 231 (96 NDR, 70
NPDR, 65 PDR)
Severity of DR associated with lower folic acid and
red cell folate levels with a significant difference
between PDR and NPDR (p < 0.05)
Folate measured with
Quantaphase II folate
radioassay kit (Bio-Rad
Laboratories, Hercules, CA,
USA)
Homocysteine
(plasma)
Higher plasma levels of homocysteine in NPDR
and PDR compared to NDR, respectively (p <
0.001 in both)
Homocysteine measured
with immunoassay
Homocysteine
(serum)
Malaguarnera et al.,
2014/cross sectional
N = 330 (50 NDR, 63
NPDR, 62 PDR, 80 healthy
controls, 75 randomly
selected patients)
Homocysteine levels were significantly elevated
between groups with progressive elevation of
levels with worsening retinopathy; significant
elevation between controls and NDR (p < 0.001),
NDR vs. NPDR (p < 0.001) and NPDR vs. PDR (p
< 0.001)
Measured using the method
of Asaki and Sako
NT-proBNP
(serum)
Hamano et al. (2014)/cross
sectional
N = 277 (60 diabetics with
no vascular complications
and 217 with micro or
macrovascular
complications—out of these
217, 74 had DR, 83.7% with
NPDR and 16.3% with PDR)
Odds ratio of having retinopathy was 13.78 in
patients with NT-proBNP in the highest tertile
independent of age, sex, duration or diabetes,
HbA1c and BMI.
Two-site sandwich
electrochemiluminescence
immunoassay (ECLusys
proBNP; Hoffman-La Roche
Ltd, Basel, Switzerland)
PEDF (plasma) Ogata et al., 2007/cross
sectional
N = 145 (12 NDR, 16
NPDR, 39 severe NPDR, 45
PDR, 33 healthy controls)
Diabetic patients had significantly higher plasma
PEDF vs. healthy controls (p = 0.03), statistically
significant rise in plasma PEDF in PDR vs. healthy
controls (p = 0.005); no significant difference
between the other diabetic retinopathy groups.
ELISA Kit (Chemikine PEDF
Sandwich ELISA Kit;
Chemicon Internation,
Temecula, CA)
BDNF Liu et al., 2016/cross
sectional
N = 344 (251 NDR, 46
non-vision threatening DR,
47 vision threatening DR)
Plasma BDNF was significantly lower in diabetics
with DR compared to those without DR (p <
0.001) with adjusted OR 0.79 (95% CI,
0.73–0.85); also for diabetics with VTDR
compared to all NDR and those with non-VTDR
(p < 0.001) and adjusted OR 0.61 (95% CI,
0.57–0.70)
BDNF: sandwich ELISA kit
(DuoSet ELISA
Development, R&D
Systems, Inc USA)
(Continued)
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TABLE 4 | Continued
Substance
analyzed
Reference/Study method Patient population Key findings Method of analysis
S100A12
@calgranulin C
@ EN-RAGE
(plasma)
Dong et al., 2015/cross
sectional (with respect to eye
markers; prospectively
followed for occurrence of
macrovascular events)
N = 372 (113 NDR, 42 mild
NPDR, 35 moderate NPDR,
38 severe NPDR, 36 PDR,
108 healthy controls)
Plasma levels of SA10012 independently
associated with presence of DR in pts with T2DM
(odds ratio 1.421, confidence interval
1.036-2.531; AUC of ROC curves using log
SA100A12 0.822 (p < 0.001)
S100A12 and pentosidine:
ELISA (Cusabio, Wuhan,
China)
hsCRP, sRAGE,
pentosidine
No significant correlation with hsCRP, pentosidine
or sRAGE levels
hsCRP: at Clincal
Diagnostic Laboratory
sRAGE: ELISA(Biovendor
Laboratorni Medicina)
PEDF, pigment epithelium derived factor; BDNF, brain derived neurotrophic factor; LXA4, Lipoxin A4; hsCRP, high sensitivity C reactive protein; IL-6, interleukin 6; IFNγ , Interferon
Gamma; TNF- α, Tunour Necrosis Factor alpha; sRAGE, soluble receptor for advanced glycation end-products; NDR, diabetic with no retinopathy; NPDR, no proliferative diabetic
retinopathy; PDR, proliferative diabetic retinopathy, VTDR, vision threatening diabetic retinopathy.
TABLE 5 | Summary of selected studies utilizing proteomics technology on various samples to determine novel proteins associated with presence of
varying stages of diabetic retinopathy.
Sample
analyzed
Reference/study design Sample size Key findings Method of analysis
Serum Kim et al., 2013/cross
sectional
N = 60 (15 NDR, 15 mild
NPDR, 15 moderate NPDR,
and 15 severe NPDR)
Twenty-eight candidate proteins were
identified that underwent changes in
expression with progression of retinopathy.
Combinations of four of these proteins
were able to distinguish between mild,
moderate, and severe NPDR generating
AUC values (>0.7) (see main text for
details)
Multiple reaction monitoring
(MRM) using triple quadrupole
LC-MS/MS (4000 QTrap coupled
with nano Tempo MDLC, Applied
Biosystems)
Serum Liu et al., 2011/cross
sectional
N = 32 (8 NDR, 8 NPDR, 8
PDR, 8 healthy controls)
Four low abundance proteins identified
(β2-GPI, AHSG, α1-AGP, apo A1); β2-GPI
expression increased with progressive
severity of DR (NDR vs. NPDR ratio 1.58;
NDR vs. PDR ration 1.84) PDR vs. NPDR
no significant rise (ratio = 1.17)
2D-DIGE
Tear fluid Csosz et al., 2012/cross
sectional
N = 145 (119 diabetics with
NDR, NPDR and PDR, 26
healthy volunteers
Six proteins were identified as possible
markers of DR in tear fluid (lipocalin 1,
lactotransferrin, lacritin, lysozyme C,
lipophilin A, and immunoglobulin lambda
chain)
Nano HPLC couples with
ESI-MS/MS mass spectrometry
Tear fluid Kim et al., 2012/cross
sectional
N = 41 (NDR 10, NPDR 17,
healthy controls 14)
Twenty proteins were differentially
expressed between the study groups,
three of which were confirmed by Western
Blot (LCN-1, HSP 27, B2M)
ESI-Q-TOF MS/MS
NDR, diabetic with no retinopathy; NPDR, no proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; 2D-DIGE, two dimensional fluorescence difference gel
electrophoresis; β2-GPI, beta 2- glycoprotein I, AHSG, alpha2-HS-glycoprotein; α1-AGP, alpha1acid glycoprotein, apo A1, apolipoprotein A1; LCN1, lipocalin 1; HSP 27, heat shock
protein 27; B2M, beta-2 microglubulin.
however further analysis using Tukey’s multiple comparisons
showed significant differences only between control and NPDR,
controls and PDR, and no DR and PDR. The lack of significance
between no DR and NPDR groups seems to cast some doubt on
its potential as a screening marker of early disease.
Ozturk et al. (2009) performed a cross sectional study with 49
patients with NPDR and 46 with PDR vs. 31 diabetics without DR
and 28 normal controls and their findings were that the median
serum VEGF level showed a statistically significant difference
(p > 0.05) between all groups except between NPDR and PDR.
The finding of significance between NDR and NPDR agree with
Du et al. (2014) but contradict the findings of Jain et al. (2013),
however the relatively small sample sizes as well as geographic
variation in the patient population may account for this.
Cavusoglu’s et al. (2007) findings were also from cross
sectional data looking at 31 patients with NPDR, 34 patients with
PDR and 18 healthy controls. VEGF levels increased significantly
between those with NPDR and PDR (p < 0.016) however they
did not include a group of diabetics without eye disease as
comparison for the VEGF levels which limits the ability to
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comment on its ability as a screening marker in this particular
study.
Although each individual study above had a relatively small
number of patients with eye disease in each cohort the consistent
finding of a statistically significantly increasing serum or plasma
level of VEGF with increasing disease severity was notable;
making it a potentially viable clinical marker for DR presence and
severity.
Inflammatory Markers (Table 3)
While it clear that inflammation is key to the pathophysiology
of DR, inflammation is also strongly associated with the other
microvascular complications of DR, suggesting that use of
markers of inflammation alone may not be sufficient as a unique
marker of DR. Perhaps further work may elucidate particular
isoforms unique to retinal pathology which may be more specific
as screening markers.
Among all the studies reviewed, perhaps the most significant
is the work done as a follow up to the DCCT trial which was
a prospective trial with a large patient cohort. One of very few
prospective studies found, this work highlighted the predictive
role of markers of inflammation and endothelial dysfunction
on the course of DR. A cohort of 1391 type 1 diabetics
with either mild or moderate retinopathy or albuminuria or
completely free of complications were followed up and carefully
assessed over a period of 16–20 years for 3-step progression
from baseline in retinopathy score; and the results show that
high levels of soluble E-selectin (sE-selectin) and Plasminogen
activator inhibitor 1 (PAI 1) at baseline are associated with
development of retinopathy in patients who had no retinopathy
at baseline. Increased levels of PAI 1 also correlated with risk of
progression to severe pre-proliferative or proliferative DR (Rajab
et al., 2015). This suggests that these markers of endothelial
dysfunction and decreased fibrinolysis may be indicative of
retinopathy development and progression. Another key finding
in this study was that while conventional inflammation markers
did show elevated levels in patients with retinopathy, they
had no predictive value for the development/progression
of retinopathy. This suggests that conventional markers of
inflammation may enable the presence of existing retinopathy
to be identified but cannot predict retinopathy progression or
development.
Sasongko et al. (2014) analyzed serum hsCRP in 224
subjects—24 NDR, 144 with mild to moderate NPDR (defined
as non-vision threatening) and 57 with severe NPDR or
PDR (defined as vision-threatening). The study found that in
vision threatening vs. non-vision threatening DR, there was
a statistically significant increase in serum hsCRP level in
a multiple regression model (OR 1.3; 95% CI 1.1–1.5). The
association was more prominent in patients with a BMI ≥
30 kg/m2 (OR 2.7 vs. OR = 1.7 for non-obese group at
same hsCRP level). However, again, there was no significant
difference between NDR and non-vision threatening DR. This
study also measured the levels of sICAM-1, VCAM-1, E-selectin,
endothelin-1, and total nitrite but none of these shown a
correlation with DR.
It has recently also been found that plasma levels of pentraxin
3 (PTX3, an acute phase reactant which reflects impaired vascular
endothelial function) are associated with the development and
progression of DR in Korean patients with Type 2 diabetes
mellitus (Yang et al., 2014). This was a case-control study which
recruited 163 subjects—92 diabetic patients with DR, 30 diabetics
with no DR and 41 healthy controls where plasma levels of PTX3
and hsCRP were measured and compared. Of the 92 patients
with DR, 28 had mild NPDR, 21 had moderate NPDR, 23 had
severe NPDR, and 20 had PDR. The proportion of higher-degree
retinal complications increased in direct correlation with log
PTX3 levels with a P trend < 0.001 whereas a similar analysis
based on log hsCRP values had a P trend of 0.006. Based on
PTX3 and hsCRP levels selected based on receiver operating
curves, the diagnostic sensitivity of PTX3 for DR was 53.3%
and sensitivity 91.7% while for hsCRP it was 51.1 and 70.8%,
respectively. The authors therefore suggested that PTX3 may
be a more accurate predictor of DR development than hsCRP.
The presence of elevated PTX3 levels from early disease and its
progressive elevation with increasing disease severity seem to
suggest it has potential as a screening marker.
Serum α2 antiplasmin is an additional inflammatory marker
which has been shown to increase with increasing disease
severity. A recent cross sectional study showed a significant
difference between serum α2 antiplasmin in NDR and DR
patients and, of particular note, it showed significantly elevated
levels even in early eye disease (p< 0.05 for NPDR and p< 0.001
for PDR in comparison to NDR; Polat et al., 2014). This study
enrolled 52 diabetic patients (21 without DR, 18 with NPDR, and
13 with PDR) and 40 healthy controls. PAI-1 was found to be
elevated in patients with DR but did not reach significance. The
true importance of these markers may be their role in predicting
progression or development of DR rather than detecting its
presence as suggested by Rajab et al. (2015).
The mean serum nitric oxide (NO), soluble interleukin-
2 receptor (sIL2R), interleukin- 8 (IL-8), and tumor-necrosis
factor-alpha (TNF-alpha) levels have been shown to increase with
the stage of DR with the highest levels being found in patients
with PDR (Doganay et al., 2002). This was a cross sectional
study which recruited 19 patients with PDR, 18 with NPDR, and
16 diabetics with no retinopathy as well as 15 healthy controls.
The levels of NO, sIL2R, and TNF-alpha showed a statistically
significant increase for PDR patients compared to that of NPDR,
no DR and controls (p < 0.001) as well as for NPDR vs. no DR
and controls (p < 0.01). There was no statistically significant
difference in serum levels of these markers between diabetic
patients without eye disease compared to controls (p > 0.05).
This was one of very few studies that was able to demonstrate
a significant rise in non-specific inflammatory markers with DR,
and the strength of the findings is limited by the small sample
size.
Regulated on Activation, Normal T-cell Expressed and
Secreted (RANTES) and stromal derived factor—1α (SDF-1α)
were shown to be significantly elevated (p < 0.001 for RANTES
and p < 0.007 for SDF-1α) in patients with at least severe NPDR
compared with those with less severe DR (Meleth et al., 2005).
This cross sectional study analyzed serum from 93 patients—62
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with less severe forms of DR and 31 patients with severe NPDR
or worse. However, drawing more definite conclusions about
their potential as screening tools is limited by the lack of healthy
controls and diabetics with no eye disease in this study. Some of
the studies reviewed also included various inflammatory markers
in the panels of substances analyzed but found limited correlation
with DR (Dong et al., 2015; Kaviarasan et al., 2015). These are
included in the relevant tables.
Overall, most of the inflammatory markers reviewed lack the
ability to consistently detect DR in its early stages—they may be
of more use in aiding determination of disease severity rather
than diagnosing new disease. However, Rajab’s work suggests that
certain markers may be of predictive value which would make
them excellent screening targets particularly in newly diagnosed
diabetics.
Other Markers (Table 4)
Awide variety of additional markers have been studied. However,
most of these markers have only been the subject of one or at
the most two relatively small studies, making it difficult to make
any definitive conclusions about their true efficacy as screening
markers.
Among the studies reviewed, one of the more promising
markers of early DR appears to be S100A12, a calcium binding
proinflammatory protein also known as calgranulin C or
extracellular newly identified receptor for AGE binding protein
(EN-RAGE) (Dong et al., 2015). This molecule (a calcium
binding pro-inflammatory protein) appears to have promise
as a marker of DR as it was shown to be independently
associated with DR by Dong et al. (2015) who performed a
cross sectional study of markers of DR with 372 subjects (113
NDR, 42 mild NPDR, 35 moderate NPDR, 38 severe NPDR,
36 PDR, and 108 healthy controls). They found that plasma
S100A12 levels were independently associated with the presence
of DR in patients with T2DM (odds ratio 1.421, 95% CI
1.036–2.531, p = 0.033). LogS100A12 values showed significant
differences between groups with progressive severity of DR.
Receiver operating curves (ROC) of log S100A12 concentration
in the plasma were able to select a value of 90.16ng/mL to provide
a diagnostic sensitivity and specificity for DR development of
78.1 and 77.0%, respectively; area under the curve was 0.822
(p < 0.001) suggesting that plasma levels of S100A12 might
be a promising predictive biomarker of DR. On follow up of
these patients, SA100A12 at baseline also appeared to correlate
with occurrence of macrovascular events. The levels of hs-CRP,
pentosidine, and sRAGE were also analyzed but did not show
significant correlation with DR severity.
Serum levels of chemerin, a multifunctional peptide involved
in lipid and glucose metabolism (Fatima et al., 2015) has also
been found to be elevated in patients with NPDR and PDR
(Du et al., 2016). This study analyzed 60 T2DM patients (15
with PDR, 20 with NPDR, and 25 with no DR) and 20 healthy
controls. Among the diabetic patients the serum chemerin levels
were demonstrated to increase with increasingly severe eye
disease; the difference in chemerin was statistically significant
(p < 0.05) between the three groups. A trend chi-square showed
that the chemerin level was correlated with the severity of
DR (χ2 = 16.07, p < 0.001). In addition, levels of chemerin
were also found to correlate positively with levels of other
markers associated with markers of obesity, inflammation, and
neovascularization namely CRP and VEGF. While these findings
are promising, the significance of this study is limited by the small
patient numbers.
Apelin-13, a ligand of G-protein coupled receptor which has
been shown to be involved in retinal angiogenesis was also
targeted as a potential biomarker (Du et al., 2014). This study
recruited 69 type 2 diabetics, 16 with PDR, 23 with NPDR, and 30
with NDR. Serum levels of apelin-13 were significantly elevated
in the PDR group compared to the no DR group (p = 0.041).
However, there was no significant difference in apelin-13 levels
between the NPDR and NDR group limiting its promise as a
screening marker.
Recent work in Japan also suggest that N-terminal fragment
on probrain natriuretic peptide (NT-proBNP) is associated with
comorbid diabetic microvascular complications with a strong
correlation for DR (Hamano et al., 2014). This was a cross
sectional study which recruited 277 subjects (60 diabetics with
no vascular complications and 217 with micro or macrovascular
complications—out of these 217, 74 had DR, 83.7% with NPDR,
and 16.3% with PDR). The odds ratio for DR was found to be
13.78 (95% CI 3.34–70.75) in the highest tertile of NT-proBNP
compared to the lowest tertile; and the elevation of this marker
in DR was independent of disease duration in addition to kidney
function or age. However, as the DR patients appear to have been
analyzed as a single group rather than by severity of DR it is
difficult to gauge whether NT-proBNPmay be a potential marker
for early retinopathy.
While PEDF levels have been found to be reduced in the
vitreous in DR (Ogata et al., 2002; Boehm et al., 2003), serum
levels have been demonstrated to be elevated in type 1 (Jenkins
et al., 2007) and type 2 diabetes (Jenkins et al., 2008) with a
correlation to microvascular complications in type 1 diabetes;
but with no specific association with DR. Other work showed
higher levels of plasma PEDF in patients with PDR Ogata et al.,
2007). This study recruited 145 patients—112 with T2DM (no
DR = 12, mild to moderate NPDR = 16, severe NPDR =
39, PDR = 45) and 33 healthy controls. Overall, patients with
diabetes were found to have a higher plasma PEDF compared to
healthy controls (p = 0.03). There was a statistically significant
rise in plasma PEDF for PDR vs. healthy controls (p = 0.005)
but there was no significant difference between the other
diabetic retinopathy groups. While it is premature to form any
conclusions, PEDF may not be one of the more promising blood
markers of DR; demonstrating that markers in the vitreous may
not necessarily translate to reliable markers in the serum or
plasma.
There has also been interest in measuring serum levels of
neuroprotective factors which have been demonstrated to be
reduced in the vitreous in diabetics. Serum levels of brain derived
neurotrophic factor (BDNF) were shown to be significantly lower
in NPDR and PDR patients compared to healthy controls in
a trial analyzing a total of 114 patients (27 NDR, 30 NPDR,
30 PDR, and 27 healthy controls; Kaviarasan et al., 2015).
However, the lack of significance in comparison to diabetics with
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no eye disease again argues against its viability as a screening
marker.
Decreased plasma levels of BDNF were also demonstrated to
be an independent risk factor in DR in the Chinese population
(Li et al., 2002). This study enrolled 344 patients with diabetes,
out of whom 93 were found to have DR—46 with non-vision
threatening DR, and 47 with vision threatening DR (VTDR)
which was defined as PDR and/or diabetic macular edema. This
study found that plasma BDNF levels were significantly lower in
all DR compared to diabetics with no eye disease (p < 0.001)
and also among those with VTDR compared to those with no
eye disease and non-VTDR (p< 0.001). Based on ROC curves, it
was suggested that a plasma BDNF level of less than 13.6 ng/mL
was suggestive of DR in general (non-VTDR and VTDR) while
a level of <12.4 mg/mL was suggestive of VTDR. As this study
did not analyse the non-VTDR as a separate group, it is difficult
to make any conclusions on the potential of BDNF as a screening
marker for early disease based on the available data.
Recently, there has also been interest in measuring substances
whose blood levels are known to be altered as a result of
the metabolic derangements that are characteristic of DM
in relation to their association with DR to assess their
potential as biomarkers. These include folate, homocysteine, and
lipoprotein (a).
Serum homocysteine levels were measured in 330 subjects (50
NDR, 63 NPDR, 62 PDR, 80 healthy controls, and 75 randomly
selected patients). The homocysteine levels showed a significant
elevation between the groups with progressive severity of DR—
comparison between controls and NDR, NDR vs. NPDR and
NPDR vs. PDR showed significance levels of p < 0.001, p <
0.001, and p < 0.0001, respectively. This seems to indicate that
homocysteine may be a promising screening marker of DR
(Malaguarnera et al., 2014).
Folate status is typically reduced in diabetic patients, and as
folate may influence the DNA stability and integrity as well as
affect the methylation patterns in neural tube tissue this may
predispose patients to the development of DR. Malaguarnera
et al. (2015) analyzed the plasma levels of folate in 231
subjects (96 NDR, 70 NPDR, and 65 PDR). Severity of diabetic
retinopathy was associated with lower folic acid and red cell folate
levels and a significant difference was observed between the PDR
and NPDR groups (p < 0.05). However, the lack of a significant
difference between NDR and NPDRmakes it less likely to be able
to be a stand-alone marker of DR.
Serum lipoprotein (a) levels have also been demonstrated to be
elevated in patients with DR compared to patients with no DR. In
a comparison of 78 diabetics with no eye disease against 67 with
DR, elevated levels of Lp(a) were found in 78.3% of those with
DR but in only 21.75% of those with no DR (Malaguarnera et al.,
2013). This seems unlikely to be a worthwhile marker for further
study.
NOVEL PROTEINS (TABLE 5)
A new era in proteomics technologies has opened new vistas in
the search for novel biomarkers of DR. The previous sections
review studies utilizing known molecules which were postulated
as likely to have a role in DR and their levels were then
measured by means of quantitative assays (largely ELISA),
however proteomics has opened up the possibility of searching
for molecules which had not yet been associated with DR but
which show altered levels on analysis of biological samples from
patients with DR.
The initial approach involved using this proteomics
technology to analyze the vitreous of patients with PDR (Kim
et al., 2007; Shitama et al., 2008). Subsequently comparisons
were made between the proteomes of vitreous and serum in
non-diabetic controls, NPDR and PDR patients which was
able to identify several biomarker candidates for NPDR (Kim
et al., 2010). The potential candidate proteins identified were
then studied further and 28 candidate proteins were found to
undergo changes as patients progressed from mild to moderate
NPDR (Kim et al., 2013). Combinations of four markers
from these 28 candidate proteins were shown to be able to
differentiate between NDR, mild NPDR, and moderate NPDR.
Specifically, complement factor H, prothrombin, apolipoprotein
A-I, and α-macroglobulin were specifically altered (increased
or decreased) preferentially in mild NPDR but did not change
in patients with no apparent DR or moderate NPDR. Using
logistic regression analysis, these four markers were able to
correctly classify 30 cases of mild NPDR from those with
no apparent disease with 83.3% accuracy. With reference to
moderate NPDR, a combination of four markers (afamin,
apolipoprotein C-III, complement factor B, and kallistatin)
was able to demonstrate 100% accuracy in differentiating
patients with moderate NPDR from those without DR. This is
a very encouraging finding and suggests that a panel of these
biomarkers may increase the likelihood of being able to screen
for and make reasonable estimates of the stage of DR in the
population.
An additional novel method utilizing proteomic technology
has been the analysis of tear fluid as a potential screening agent
for DR. It has been noted that studies using serum to evaluate
for biomarkers of DR faced difficulties due to the fact that serum
from diabetic patients contained several glycosylated proteins.
Tear fluid was postulated to be an accurate and efficient way
of screening for DR; furthermore tear fluid is easily obtained
through non-invasive methods. Evaluation of the proteome
of tear fluid has been found to have significant differences
between patients with early DR and healthy controls (Csosz
et al., 2012; Kim et al., 2012). An attempt to apply machine
learning algorithms to the variable protein concentration of
six proteins identified by Csosz et al. (2012) as independent
biomarkers of DR in tear fluid was able to obtain 74% sensitivity,
48% specificity and 65% accuracy highlighting the potential of
tear fluid as a promising biological sample to screen for DR
(Torok et al., 2013).
MICRORNA (miRNA)
miRNAs are a class of highly conserved 19–25 nucleotide
noncoding RNAs that regulate gene expression at
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the posttranscriptional level. By annealing to partially
complementary sequences in the target mRNAs, miRNAs
mediate translational repression or degradation of mRNAs,
resulting in the downregulation of protein expression (Wu
et al., 2012). There is evidence that several miRNAs target
specific mRNAs for regulating the progression of DR. These
include miRNAs-126, -200b, and -31, all of which are involved in
vasculature regulation and therefore are crucial for suppressing
angiogenesis in DR. miRNAs-146, -155, -132, and -21 have role in
the chronic inflammation that is a key factor in the development
of DR (Xiong et al., 2014). Other miRNAs whose level has been
shown to be altered in patients with DR but whose role remains
to be clearly defined include miR-182, -96, -183, -211, -204, and
-124 which were significantly increased during progress of DR,
and miR-10b, -10a, 219-2-3p, -144, -338, -199a-3p which were
significantly decreased (Wu et al., 2012). Others with altered
levels include miR-24, -323, -92a, -369, -219, -203a,-34c, -350,
-410, -592, -758, -216a, -351, -137, -935 (upregulated), and
miR-375 and -212 which are downregulated (Xiong et al., 2014).
Recent work based on a nested case-control study design of 300
samples in two prospective cohorts of the Diabetic Retinopathy
Candesartan Trial (DIRECT): PROTECT-1 and PREVENT-1
has identified two angiogenic miRNAs miR-320a and -27b as
potential biomarkers for diabetic retinopathy (Zampetaki et al.,
2016).
miRNAs are deemed to show great promise as biomarkers.
Although the main biological activity of miRNA occurs in the
intracellular space, these molecules have been found to be stable
in many biological fluids, including human serum, plasma, urine,
saliva, tears, aqueous humor, and vitreous humor (Mastropasqua
et al., 2014) which makes them potentially detectable in wide
variety of easily obtainable clinical specimens. Also, they are
very stable and long lived molecules. Once released from cells
into circulation, they have a long life span (∼≥2 weeks) and
they are stable in plasma, serum and urine not only under
standard conditions but also after undergoing several freeze-
thaw cycles, strong variation in pH, and long exposure to
room temperature as well as having efficient recovery and the
fact that quantitative assays to measure these molecules are
currently available (Mastropasqua et al., 2014; Joglekar et al.,
2016).
CONCLUSION
At present, a definitive marker for early stage DR or one that
can be detected well-before the development of any retinopathy
remains elusive. However, the findings of the two prospective
studies done with the DCCT cohort have demonstrated
promising markers of increased risk for development and
progression of DRwhich should be pursued further.While a large
number of other potential markers have been suggested by the
other studies reviewed, their cross sectional study design makes
the conclusions drawn less robust. An additional consideration
from the work reviewed is that the multifactorial etiology of DR
makes it likely that a successful screening strategy may require
a panel of markers as opposed to utilizing a single marker; also
serummarkers of DRmay not necessarily correspond to markers
of DR found in the vitreous.
There are multiple potential confounders that need to be
addressed in the search for a screening marker, including
geographic, ethnic, and genetic variations in the study
populations as well as the varying phenotypes of DR. Large
scale, multicenter prospective studies need to be done in order to
conclusively determine the reliability of the various biomarkers
of early stage DR.
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